Methods

This is a case-control study matched for age and gender. Recruitment of patients diagnosed with BD was performed in the Bipolar Disorders Program of Hospital de Clínicas in Porto Alegre, Brazil as well as the enrolment of positive controls, defined as first-relatives of patients with BD.

Objectives

The aims of our study were to investigate the role of interleukin-6 (IL-6) in the model of staging and to detect clinical predictors of variations in IL-6 levels.

Results

A significant increase in IL-6 was found among the four groups of patients according to the classification of staging ($F=2.85$, $p=0.04$).

Conclusions

Interleukin-6 may be a useful biomarker in the model of staging in bipolar disorder and could be related to the density of episodes and early onset of the disorder.

Bibliography


Disclosures

Dr. I. Grande has received a research grant from Hospital Clinic de Barcelona (HCB). Prof. E. Vieta has received research grants, and served as consultant, advisor or speaker for the following companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Lundbeck, Merck Sharp & Dohme, Novartis, Otsuka, Pfizer Inc, Sanofi-Aventis, Servier, Takada, and UBIC. Prof. Kapczinski has received grant/research support from AstraZeneca, Eli Lilly, Janssen-Cilag, Servier, CNPq, CAPES, NARSAD and Stanley Medical Research Institute; has been a member of the speakers’ boards for Astra-Zeneca, Eli Lilly, Janssen-Cilag and Servier; and has served as a consultant for Servier.